AtriCure (ATRC) Competitors $31.50 +1.33 (+4.41%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$31.54 +0.05 (+0.14%) As of 07/25/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATRC vs. TFX, ITGR, ATEC, IART, SRDX, OFIX, ANGO, ARAY, RMTI, and RSLSShould you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Teleflex (TFX), Integer (ITGR), Alphatec (ATEC), Integra LifeSciences (IART), Surmodics (SRDX), Orthofix Medical (OFIX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), and ReShape Lifesciences (RSLS). These companies are all part of the "health care equipment" industry. AtriCure vs. Its Competitors Teleflex Integer Alphatec Integra LifeSciences Surmodics Orthofix Medical AngioDynamics Accuray Rockwell Medical ReShape Lifesciences AtriCure (NASDAQ:ATRC) and Teleflex (NYSE:TFX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings. Which has better earnings & valuation, ATRC or TFX? Teleflex has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtriCure$465.31M3.35-$44.70M-$0.81-38.89Teleflex$3.05B1.70$69.68M$3.1736.99 Do analysts prefer ATRC or TFX? AtriCure presently has a consensus target price of $50.67, indicating a potential upside of 60.85%. Teleflex has a consensus target price of $159.63, indicating a potential upside of 36.14%. Given AtriCure's stronger consensus rating and higher probable upside, research analysts clearly believe AtriCure is more favorable than Teleflex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AtriCure 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Teleflex 1 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.09 Do insiders & institutionals believe in ATRC or TFX? 99.1% of AtriCure shares are held by institutional investors. Comparatively, 95.6% of Teleflex shares are held by institutional investors. 3.5% of AtriCure shares are held by company insiders. Comparatively, 1.4% of Teleflex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer ATRC or TFX? In the previous week, Teleflex had 6 more articles in the media than AtriCure. MarketBeat recorded 11 mentions for Teleflex and 5 mentions for AtriCure. AtriCure's average media sentiment score of 1.14 beat Teleflex's score of 1.00 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teleflex 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, ATRC or TFX? AtriCure has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. Comparatively, Teleflex has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Is ATRC or TFX more profitable? Teleflex has a net margin of 4.96% compared to AtriCure's net margin of -7.95%. Teleflex's return on equity of 14.73% beat AtriCure's return on equity.Company Net Margins Return on Equity Return on Assets AtriCure-7.95% -5.68% -4.34% Teleflex 4.96%14.73%8.79% SummaryAtriCure and Teleflex tied by winning 8 of the 16 factors compared between the two stocks. Get AtriCure News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRC vs. The Competition Export to ExcelMetricAtriCureMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.49B$10.55B$5.70B$9.50BDividend YieldN/A2.00%4.60%4.01%P/E Ratio-38.8917.0728.1020.05Price / Sales3.3529.18429.3789.38Price / CashN/A23.0336.2258.56Price / Book3.333.698.665.87Net Income-$44.70M$234.77M$3.25B$258.55M7 Day Performance7.66%6.32%4.22%3.73%1 Month Performance-4.20%7.94%10.51%11.75%1 Year Performance42.53%-13.57%34.40%18.03% AtriCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRCAtriCure3.3316 of 5 stars$31.50+4.4%$50.67+60.8%+33.9%$1.49B$465.31M-38.891,300News CoveragePositive NewsUpcoming EarningsTFXTeleflex4.8676 of 5 stars$115.78-0.5%$164.63+42.2%-47.3%$5.12B$3.01B36.5214,100Positive NewsUpcoming EarningsITGRInteger3.3893 of 5 stars$119.61-0.3%$145.00+21.2%-6.5%$4.17B$1.72B56.6911,000Trending NewsEarnings ReportAnalyst ForecastATECAlphatec3.9107 of 5 stars$10.91-0.7%$17.89+64.0%-0.5%$1.59B$642.27M-9.49700News CoveragePositive NewsUpcoming EarningsIARTIntegra LifeSciences4.1407 of 5 stars$12.21-3.0%$18.63+52.5%-58.4%$948.84M$1.61B-32.134,396News CoverageUpcoming EarningsSRDXSurmodics4.0254 of 5 stars$31.39+1.7%$43.00+37.0%-13.4%$448.88M$126.08M-22.58450News CoverageUpcoming EarningsOFIXOrthofix Medical2.7408 of 5 stars$10.98-0.6%$21.50+95.8%-31.7%$430.20M$799.49M-2.981,616ANGOAngioDynamics3.9515 of 5 stars$9.63+3.3%$14.00+45.4%+22.8%$391.05M$283.32M-9.53760High Trading VolumeARAYAccuray3.1256 of 5 stars$1.36flatN/A-27.3%$140.10M$465.25M0.001,040News CoveragePositive NewsRMTIRockwell Medical3.9965 of 5 stars$1.11-1.8%$4.00+260.4%-42.2%$37.93M$97.73M0.00300Positive NewsRSLSReShape Lifesciences0.4256 of 5 stars$2.39+0.4%N/A-99.2%$5.71M$8.01M-0.0150Positive News Related Companies and Tools Related Companies TFX Competitors ITGR Competitors ATEC Competitors IART Competitors SRDX Competitors OFIX Competitors ANGO Competitors ARAY Competitors RMTI Competitors RSLS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATRC) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
